表紙
市場調查報告書
商品編碼
910605

血小板減少性疾病 (免疫性,化療誘發性)的全球市場:考察、趨勢、未來預測

Global Thrombocytopenia (Immune & Chemotherapy-induced) Market: Insights, Trends and Forecast (2019-2023)

出版日期: | 出版商: Koncept Analytics | 英文 95 Pages | 訂單完成後即時交付

價格
  • 全貌
  • 簡介
  • 目錄
簡介

本報告提供全球血小板減少性疾病的市場相關分析,整體市場規模趨勢預測 (今後5年份) ,及各類型 (免疫性血小板減少性疾病 (ITP),化療誘發性血小板減少性疾病 (CIT) 等) 及各地區詳細趨勢,主要的推動及阻礙市場要素,企業間的競爭狀態、業績比較,主要企業簡介等調查。

第1章 概要

第2章 全球血小板減少性疾病市場

  • 免疫性血小板減少性疾病 (ITP) 市場
    • 市場規模 (以金額為準,預測值)
    • 患者數 (人數,預測值)
    • 患者數:各地區 (人數,預測值)
    • 已治療患者數 (人數,預測值)
    • 已治療患者數:各地區 (人數,預測值)
  • 化療誘發性血小板減少性疾病 (CIT) 市場
    • 患者數 (人數,預測值)
    • 患者數:各地區 (人數,預測值)
    • 已治療患者數 (人數,預測值)
    • 已治療患者數:各地區 (人數,預測值)

第3章 各地區的血小板減少性疾病市場

  • 美國市場
    • ITP (免疫性血小板減少性疾病):患者總數的預測
    • ITP:已治療患者數的預測
    • ITP:以Doptelet治療的患者數的預測
    • CIT (化療誘發性血小板減少性疾病):患者總數的預測
    • CIT:已治療患者數的預測
    • CIT:以Doptelet治療的患者數的預測
    • CLD (慢性肝疾病):患者數的預測
    • CLD:併發了重度的血小板減少性疾病的患者數的預測
    • CLD:併發了重度的血小板減少性疾病,已治療患者數的預測
  • 其他國家 (RoW)的市場
    • ITP:患者總數的預測
    • ITP:已治療患者數的預測
    • CIT:患者總數的預測
    • CIT:已治療患者數的預測

第4章 市場動態

  • 成長促進因素
  • 主要趨勢和動靜
  • 課題

第5章 競爭環境

  • 全球市場
    • 主要企業:現在可提供,慢性血小板減少性疾病用醫藥品
    • 主要企業:研究開發 (R&D)的比較
    • 主要企業:市場收益額比較
    • 主要企業:股票市值比較

第6章 企業簡介

  • Novartis AG
    • 產業概要
    • 主要的財務指標
    • 事業策略
  • Merck & Co.
  • Amgen Inc.
  • CSL Limited
  • Horizon Therapeutics
  • Rigel Pharmaceuticals
目錄

The global immune thrombocytopenia (ITP) market is expected to reach 2.27 billion in 2023, growing at a CAGR of 5.82%, for the duration spanning 2019-2023. The factors such as, rising healthcare expenditures, growing female population, rising prevalence of arthritis, increasing incidences of hepatitis C and new cases of diagnosed cancer would drive the growth of the market. However, market growth would be challenged by the lethargic drug approval process, side effects associated with available thrombocytopenia drugs and the availability of alternative treatment options. A few notable trends include, novel drug development for thrombocytopenia, increasing number of awareness programs against thrombocytopenia, and increasing preferences for biosimilars.

The global thrombocytopenia market would witness considerable growth in coming years, due to the rising prevalence of thrombocytopenia and associated risk factors. The most common type of thrombocytopenia is ITP, which is highly prevalent in patients with rheumatoid arthritis. Whereas, CIT (Chemotherapy-Induced Thrombocytopenia) occurs in patients with cancer, due to the involvement of chemotherapy and radiation treatment. Thrombocytopenia in patients with CLD is growing rapidly with an increase in incidences of HCV infections among them.

The fastest growing regional market is the U.S., owing to the high prevalence of thrombocytopenia in patients with cancer as well as chronic liver diseases. Moreover, rising awareness about the symptoms and causes of thrombocytopenia among people, through various campaigns and the FDA approvals of various novel drugs for the treatment of thrombocytopenia would drive considerable growth in the global thrombocytopenia market.

Scope of the report:

The report provides a comprehensive analysis of the global thrombocytopenia (Immune and Chemotherapy-induced) market.

The major regional market (the U.S.) has been analyzed.

The market dynamics such as growth drivers, market trends and challenges are analyzed in-depth.

The competitive landscape of the market, along with the company profiles of leading players (Novartis AG, Merck and Co., CSL Limited, Amgen Pharmaceuticals, Horizon Therapeutics and Rigel Pharmaceuticals) are also presented in detail.

Key Target Audience:

  • Thrombocytes Drugs Manufacturers
  • Chemical Suppliers
  • End Users (Hospital, Medical Centers, Clinical Institutes)
  • Healthcare Consulting Firms
  • Investment Banks
  • Government Bodies & Regulating Authorities

Table of Contents

1. Overview

  • 1.1 Introduction
  • 1.2 Causes of Thrombocytopenia
  • 1.3 Symptoms of Thrombocytopenia
  • 1.4 Diagnosis of Thrombocytopenia
  • 1.5 Treatment of Thrombocytopenia
  • 1.6 Pathophysiology of Thrombocytopenia

2. Global Thrombocytopenia Market

  • 2.1 Global ITP Market
    • 2.1.1 Global ITP Market Forecast by Value
    • 2.1.2 Global ITP Total Patient Volume Forecast
    • 2.1.3 Global ITP Total Patient Volume Forecast by Region
    • 2.1.4 Global ITP Treated Patient Volume Forecast
    • 2.1.5 Global ITP Treated Patient Volume Forecast by Region
  • 2.2 Global CIT Market
    • 2.2.1 Global CIT Total Patient Volume Forecast
    • 2.2.2 Global CIT Total Patient Volume Forecast by Region
    • 2.2.3 Global CIT Treated Patient Volume Forecast
    • 2.2.4 Global CIT Treated Patient Volume Forecast by Region

3. Regional Thrombocytopenia Market

  • 3.1 The U.S.
    • 3.1.1 The U.S. ITP Total Patient Volume Forecast
    • 3.1.2 The U.S. ITP Treated Patient Volume Forecast
    • 3.1.3 The U.S. Doptelet ITP Treated Patient Volume Forecast
    • 3.1.4 The U.S. CIT Total Patient Volume Forecast
    • 3.1.5 The U.S. CIT Treated Patient Volume Forecast
    • 3.1.6 The U.S. Doptelet CIT Treated Patient Volume Forecast
    • 3.1.7 The U.S. CLD Patient Volume Forecast
    • 3.1.8 The U.S. CLD Patient Volume with Severe Thrombocytopenia Forecast
    • 3.1.9 The U.S. CLD Treated Patient Volume with Severe Thrombocytopenia Forecast
  • 3.2 ROW (Rest of World)
    • 3.2.1 ROW ITP Total Patient Volume Forecast
    • 3.2.2 ROW ITP Treated Patient Volume Forecast
    • 3.2.3 ROW CIT Total Patient Volume Forecast
    • 3.2.4 ROW CIT Treated Patient Volume Forecast

4. Market Dynamics

  • 4.1 Growth Drivers
    • 4.1.1 Rising HealthCare Expenditure
    • 4.1.2 Growing Female Population
    • 4.1.3 Rising Prevalence of Arthritis
    • 4.1.4 Increasing Incidences of Hepatitis C
    • 4.1.5 New Cases of Diagnosed Cancer
  • 4.2 Key Trends & Development
    • 4.2.1 Novel Drug Development for Thrombocytopenia
    • 4.2.2 Increasing Number of Awareness Programs about Thrombocytopenia
    • 4.2.3 Increase in Pharmaceutical R&D Expenditures
    • 4.2.4 Increasing Preference for Biosimilars
  • 4.3 Challenges
    • 4.3.1 Lethargic Drug Approval Process
    • 4.3.2 Side Effects Associated With Available Thrombocytopenia Drugs
    • 4.3.3 Availability of Alternative Treatment Options

5. Competitive Landscape

  • 5.1 Global Market
    • 5.1.1 Key Players - Available Drugs for Chronic Thrombocytopenia
    • 5.1.2 Key Players - R&D Comparison
    • 5.1.3 Key Players - Revenue Comparison
    • 5.1.4 Key Players - Market Cap Comparison

6. Company Profiles

  • 6.1 Novartis AG
    • 6.1.1 Business Overview
    • 6.1.2 Financial Overview
    • 6.1.3 Business Strategies
  • 6.2 Merck & Co.
    • 6.2.1 Business Overview
    • 6.2.2 Financial Overview
    • 6.2.3 Business Strategies
  • 6.3 Amgen Inc.
    • 6.3.1 Business Overview
    • 6.3.2 Financial Overview
    • 6.3.3 Business Strategies
  • 6.4 CSL Limited
    • 6.4.1 Business Overview
    • 6.4.2 Financial Overview
    • 6.4.3 Business Strategies
  • 6.5 Horizon Therapeutics
    • 6.5.1 Business Overview
    • 6.5.2 Financial Overview
    • 6.5.3 Business Strategies
  • 6.6 Rigel Pharmaceuticals
    • 6.6.1 Business Overview
    • 6.6.2 Financial Overview
    • 6.6.3 Business Strategies

List of Figures

  • Symptoms of Thrombocytopenia
  • Diagnosis of Thrombocytopenia
  • Treatment of Thrombocytopenia
  • Global ITP Market Forecast by Value (2019-2023)
  • Global Total ITP Total Patient Volume Forecast (2019-2023)
  • Global ITP Total Patient Volume Forecast by Region (2023)
  • Global ITP Treated Patient Volume Forecast (2019-2023)
  • Global ITP Treated Patient Volume Forecast by Region (2023)
  • Global CIT Total Patient Volume Forecast (2019-2023)
  • Global CIT Total Patient Volume Forecast by Region (2018/2023)
  • Global CIT Treated Patient Volume Forecast (2018-2023)
  • Global CIT Treated Patient Volume Forecast by Region (2018/2023)
  • The U.S. ITP Total Patient Volume Forecast (2019-2023)
  • The U.S. ITP Treated Patient Volume Forecast (2019-2023)
  • The U.S. Doptelet ITP Treated Patient Volume Forecast (2019-2023)
  • The U.S. CIT Total Patient Volume Forecast (2018-2023)
  • The U.S. CIT Treated Patient Volume Forecast (2018-2023)
  • The U.S. Doptelet CIT Treated Patient Volume Forecast (2021-2026)
  • The U.S. CLD Patient Volume Forecast (2018-2023)
  • The U.S. CLD Patient Volume with Severe Thrombocytopenia Forecast (2018-2023)
  • The U.S. CLD Treated Patient Volume with Severe Thrombocytopenia Forecast (2018-2023)
  • ROW ITP Total Patient Volume Forecast (2019-2023)
  • ROW ITP Treated Patient Volume Forecast (2019-2023)
  • ROW CIT Total Patient Volume Forecast (2018-2023)
  • ROW CIT Treated Patient Volume Forecast (2018-2023)
  • Global HealthCare Expenditure Per Capita (2014-2018)
  • Global Female Population (2014-2018)
  • Novel Drug Development for Thrombocytopenia (2018)
  • Awareness Programs about Thrombocytopenia (2018)
  • Global Pharmaceutical R&D Expenditures (2014-2018)
  • Drugs Approval Process
  • Key Players - R&D Comparison (2017-2018)
  • Novartis AG Net Sales and Net Income (2014-2018)
  • Novartis AG Net Sales by Segment (2018)
  • Novartis AG Net Sales by Regions (2018)
  • Merck & Co. Sales and Net Income (2014-2018)
  • Merck & Co. Sales by Segment (2018)
  • Merck & Co. Sales by Regions (2018)
  • Amgen Inc. Total Revenue and Net Income (2014-2018)
  • Amgen Inc. Total Revenue by Segment (2018)
  • Amgen Inc. Total Revenue by Regions (2018)
  • CSL Limited Total Operating Revenue and Net Profit (2014-2018)
  • CSL Limited Total Operating Revenue by Segment (2018)
  • CSL Limited Total Operating Revenue by Regions (2018)
  • Horizon Therapeutics Net Sales and Net Loss (2014-2018)
  • Horizon Therapeutics Net Sales by Segment (2018)
  • Horizon Therapeutics Net Sales by Regions (2018)
  • Rigel Pharmaceuticals Total Revenue and Net Loss (2014-2018)
  • Rigel Pharmaceuticals Total Revenue by Divisions (2018)

List of Tables

  • Causes of Thrombocytopenia
  • The U.S. Diagnosed Arthritis Population (2000-2020)
  • Hepatitis C Population in Major Regions (2018)
  • Global New Cases of Diagnosed Cancer (2018)
  • Key Players - Available Drugs for Chronic Thrombocytopenia
  • Key Players - Revenue Comparison (2018)
  • Key Players - Market Cap Comparison (2019)